This article is more than 5 years old. Information may no longer be current.
Top 5 cardiometabolic news reports from 2017
Click Here to Manage Email Alerts
Endocrine Today has compiled a list of the top five cardiometabolic news reports posted in 2017.
Healio.com/Endocrinology readers were interested in use of diabetes drugs in light of CV safety results, a group supporting patients with a rare genetic disease, effect of PCKS9 inhibitors on CV risk, and much more.
Physicians fine-tune use of diabetes drugs after recent CV safety results
In 2008, the FDA challenged developers of new diabetes drugs to prove that these agents do not increase cardiovascular risk. Results from those studies are now coming in, and beyond demonstrating safety, several are suggesting that drug classes developed over the past decade can reduce overall cardiovascular mortality and mitigate the heart failure and kidney disease that often result from diabetes. Read more.
Group supports patients with familial chylomicronemia syndrome
Familial chylomicronemia syndrome is a rare genetic disease caused by insufficient or impaired function of lipoprotein lipase, an enzyme responsible for triglyceride metabolism. This autosomal recessive disorder is caused by inherited mutations in the gene encoding for lipoprotein lipase or by mutations in genes that code for other proteins necessary for the enzyme’s proper function. Read more.
Metabolic profile differs between transgender adolescents, teens with PCOS despite testosterone levels
ORLANDO, Fla. — The profile of metabolic disease risk among adolescents transitioning from female to male and adolescents with polycystic ovary syndrome may not be similar despite elevated serum testosterone concentrations in both groups. Read more.
PCSK9 inhibitor lowers CV risk in insulin-treated type 2 diabetes
SAN DIEGO — Results of the ODYSSEY DM-INSULIN trial indicate that adults with dyslipidemia and type 2 diabetes who are taking insulin can reduce their cardiovascular risk with alirocumab, according to new data presented here. Read more.
Vitamin D status associated with early CVD markers in children with obesity
ORLANDO, Fla. — In children with overweight or obesity, low levels of serum 25-hydroxyvitamin D are associated with markers for cardiovascular disease, including elevated non-HDL cholesterol, total cholesterol and triglycerides, according to study findings presented here. Read more.